<div id="readability-page-1"><p><span>Penumbra (NYSE:PEN - Get Free Report)</span> was downgraded by stock analysts at Wells Fargo &amp; Company from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note issued on Thursday,Zacks.com reports.</p><ul><li>3 Mid-Cap Medical Stocks Outperforming the Market</li></ul><p>Several other research analysts have also recently weighed in on the company. Weiss Ratings  restated a &#34;hold (c)&#34; rating on shares of Penumbra in a report on Monday, December 29th. BTIG Research lowered Penumbra from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and set a $349.00 target price on the stock. in a report on Thursday. JPMorgan Chase &amp; Co. raised Penumbra from a &#34;neutral&#34; rating to an &#34;overweight&#34; rating and increased their price objective for the stock from $275.00 to $370.00 in a research report on Thursday, December 18th. Bank of America upped their price target on Penumbra from $320.00 to $370.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, January 5th. Finally, Needham &amp; Company LLC upped their price target on Penumbra from $326.00 to $388.00 and gave the stock a &#34;buy&#34; rating in a report on Wednesday, December 17th. Ten investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $354.38.</p><p><b>Get Our Latest Stock Analysis on PEN</b></p><h2>Penumbra Stock Performance</h2><ul><li>Are These Medical Device Makers Getting Ready To Rally? </li></ul><p>Penumbra stock opened at $350.53 on Thursday. The firm has a market capitalization of $13.73 billion, a P/E ratio of 83.86, a price-to-earnings-growth ratio of 1.92 and a beta of 0.71. The company's 50-day moving average is $301.84 and its 200 day moving average is $268.86. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.73 and a quick ratio of 4.18. Penumbra has a 1-year low of $221.26 and a 1-year high of $352.15. </p><p>Penumbra (NYSE:PEN - Get Free Report) last issued its earnings results on Wednesday, November 5th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.90 by $0.07. Penumbra had a return on equity of 11.35% and a net margin of 12.30%.The company had revenue of $354.69 million during the quarter, compared to analyst estimates of $340.77 million. During the same quarter last year, the business posted $0.85 EPS. The firm's quarterly revenue was up 17.8% on a year-over-year basis.  Research analysts forecast that  Penumbra will post 3.67 EPS for the current year. </p><h2>Insider Buying and Selling</h2><p>In other Penumbra news, Director Arani Bose sold 15,000 shares of Penumbra stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $308.82, for a total value of $4,632,300.00. Following the transaction, the director owned 258,462 shares in the company, valued at approximately $79,818,234.84. The trade was a 5.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Thomas Wilder sold 186 shares of Penumbra stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $310.72, for a total transaction of $57,793.92. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 34,144 shares of company stock valued at $10,260,127 over the last quarter. Company insiders own  4.20% of the company's stock. </p><h2>Institutional Trading of Penumbra</h2><p>Several large investors have recently made changes to their positions in PEN. Machina Capital S.A.S. bought a new position in shares of  Penumbra in the 2nd quarter worth $369,000.  First Trust Advisors LP grew its position in shares of  Penumbra by 4.0% during the 2nd quarter. First Trust Advisors LP now owns 100,723 shares of the company's stock worth $25,849,000 after buying an additional 3,906 shares during the period.  Russell Investments Group Ltd. increased its stake in shares of  Penumbra by 22.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 26,604 shares of the company's stock valued at $6,827,000 after acquiring an additional 4,960 shares during the last quarter.  Janney Montgomery Scott LLC raised its position in shares of  Penumbra by 716.5% in the 2nd quarter. Janney Montgomery Scott LLC now owns 24,749 shares of the company's stock valued at $6,351,000 after acquiring an additional 21,718 shares during the period.  Finally, Marshall Wace LLP boosted its stake in  Penumbra by 340.0% during the 2nd quarter. Marshall Wace LLP now owns 82,031 shares of the company's stock worth $21,052,000 after acquiring an additional 63,389 shares during the last quarter. Institutional investors own  88.88% of the company's stock. </p><h2>Key Penumbra News</h2><p>Here are the key news stories impacting Penumbra this week:</p><ul>   <li><span>Positive Sentiment: </span>Boston Scientific has agreed to acquire Penumbra in a cash-and-stock transaction that values Penumbra at about $14.5 billion, providing a significant premium to the prior market price and driving the stock higher. Read More.</li>    <li><span>Positive Sentiment: </span>News coverage and deal write-ups highlight strategic benefits for Boston Scientific (expanded thrombectomy and neurovascular capabilities), which supports the rationale for the acquisition premium and underpins investor enthusiasm for PEN. Read More.</li>    <li><span>Neutral Sentiment: </span>Penumbra issued a preliminary fourth-quarter and full-year 2025 results update and provided revenue guidance that was roughly in line with expectations — this supports deal valuation but will be audited and finalized. Read More.</li>    <li><span>Neutral Sentiment: </span>Analyst commentary and earnings-estimate revisions have turned more positive following the acquisition news, which can sustain near-term upside as markets reprice consensus estimates. Read More.</li>    <li><span>Negative Sentiment: </span>Several shareholder-law firms have announced investigations into whether the sale price and process were fair to Penumbra shareholders; litigation or regulatory scrutiny could delay closing or lead to renegotiation. Read More.</li> </ul><h2>About Penumbra</h2> (Get Free Report)<p>Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra's technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.  </p><p>At the core of Penumbra's portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.</p><h2>See Also</h2><ul><li>Five stocks we like better than Penumbra</li><li>Buy Alert: $8 AI Stock</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li><li>Virtually Unknown AI Company Solving Trillion-Dollar Problem</li><li>Do not delete, read immediately</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBFTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBFTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Penumbra Right Now?</h2><p>Before you consider Penumbra, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Penumbra wasn't on the list.</p><p>While Penumbra currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Wells Fargo & Company has downgraded Penumbra (NYSE:PEN) from a "strong-buy" to a "hold" rating. This change follows a series of mixed ratings from other analysts, with some maintaining a buy rating and others downgrading their outlook. Currently, Penumbra has a consensus rating of "Moderate Buy" with an average price target of $354.38. The stock opened at $350.53, with a market cap of $13.73 billion and a P/E ratio of 83.86. Recent insider trading shows significant share sales by company directors.</p>

Penumbra (NYSE:PEN) Downgraded to "Hold" Rating by Wells Fargo & Company